Seoul, South Korea-based SK Biotek will acquire Bristol-Myers Squibb's active pharmaceutical ingredient manufacturing facility in Swords, Ireland, under a deal that is anticipated to close by the fourth quarter of the year. SK Biotek will manufacture the facility's current portfolio, including BMS' and Pfizer's Eliquis, or apixaban.
SK Biotek to acquire BMS' API facility in Ireland
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.